5-amino-1mq weight loss study Peptide Therapy 5 amino 1mq nnmt inhibitor

Some research community protocols stack 5-Amino-1MQ with AOD-9604 or with a GLP-1 drug, but no human study has tested those combinations

Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available

The discussion is to confirm eligibility and potential benefits

It works by blocking NNMT, which boosts NAD+ levels and improves the bodys ability to burn stored fat